DreaMS - Digital Biomarkers for Multiple Sclerosis
Launched by RESEARCH CENTER FOR CLINICAL NEUROIMMUNOLOGY AND NEUROSCIENCE BASEL · May 29, 2020
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) causing focal lesions of demyelination and diffuse neurodegeneration in the grey and white matter of the brain and spinal cord, leading to physical and cognitive disability. Currently there is a limited number of relevant biomarkers available in patients with MS, such as clinical, imaging or biological measures. Patient history and neurologic examination in combination with magnetic resonance imaging (MRI), evoked potentials and analysis of serum and cerebrospinal fluid (CSF) are the gold standard ...
Gender
ALL
Eligibility criteria
- • Patients with MS
- Inclusion Criteria:
- • Age 18-70
- • Diagnosed with MS according to the revised McDonald criteria 2017, all clinical forms inclusive (CIS, RRMS, SPMS, PPMS)
- • EDSS ≤ 6.5
- • In possession of a smart phone
- Exclusion Criteria:
- • Age \<18 and \> 70
- • EDSS \> 6.5
- • Other clinically significant concomitant disease states (e.g., renal failure, severe hepatic dysfunction, severe/unstable cardiovascular disease, progressive cancer, etc.)
- • Known or suspected non-compliance, drug or alcohol abuse
- • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.
- • Women who are pregnant or breast feeding
- • Not in possession of a smart phone
- • Healthy Volunteers
- Inclusion Criteria:
- • Age 18-70
- • In possession of a smart phone
- Exclusion Criteria:
- • Age \<18 and \> 70
- • Diagnosis of MS
- • Clinically significant concomitant disease states (e.g., renal failure, severe hepatic dysfunction, severe/unstable cardiovascular disease, progressive cancer, etc.)
- • Known or suspected non-compliance, drug or alcohol abuse
- • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.
- • Women who are pregnant or breast feeding
- • Not in possession of a smart phone
About Research Center For Clinical Neuroimmunology And Neuroscience Basel
The Research Center for Clinical Neuroimmunology and Neuroscience Basel is a leading institution dedicated to advancing the understanding and treatment of neuroimmunological disorders. Focused on innovative research and clinical trials, the center integrates cutting-edge laboratory techniques with patient-centered approaches to develop effective therapeutic strategies. By fostering collaboration among interdisciplinary teams of experts, the center aims to translate scientific discoveries into clinical applications, ultimately improving patient outcomes in neuroimmunology and related fields.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, , Switzerland
Patients applied
Trial Officials
Ludwig Kappos, MD
Principal Investigator
University Hospital Basel and RC2NB
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials